3.15
price up icon0.32%   0.010
after-market Handel nachbörslich: 3.15
loading
Schlusskurs vom Vortag:
$3.14
Offen:
$3.13
24-Stunden-Volumen:
410.41K
Relative Volume:
0.51
Marktkapitalisierung:
$603.31M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-7.1591
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
+0.64%
1M Leistung:
-8.16%
6M Leistung:
-2.17%
1J Leistung:
-17.32%
1-Tages-Spanne:
Value
$3.12
$3.17
1-Wochen-Bereich:
Value
$3.08
$3.20
52-Wochen-Spanne:
Value
$2.705
$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name
Firmenname
Arbutus Biopharma Corp
Name
Telefon
604-419-3200
Name
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Name
Mitarbeiter
44
Name
Twitter
@arbutusbio
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
ABUS's Discussions on Twitter

Vergleichen Sie ABUS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ABUS
Arbutus Biopharma Corp
3.15 599.48M 12.99M -74.39M -78.92M -0.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-02-02 Hochstufung Jefferies Hold → Buy
2021-02-25 Eingeleitet Jefferies Hold
2020-12-17 Eingeleitet H.C. Wainwright Buy
2020-07-27 Fortgesetzt JMP Securities Mkt Outperform
2020-07-24 Herabstufung Robert W. Baird Outperform → Neutral
2020-05-19 Hochstufung Wedbush Neutral → Outperform
2020-03-06 Hochstufung Chardan Capital Markets Neutral → Buy
2020-02-20 Eingeleitet Robert W. Baird Outperform
2020-02-05 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2019-10-07 Bestätigt B. Riley FBR Buy
2019-10-04 Herabstufung Chardan Capital Markets Buy → Neutral
2018-10-16 Hochstufung B. Riley FBR Neutral → Buy
2018-10-15 Hochstufung Wedbush Underperform → Neutral
2018-10-12 Bestätigt Chardan Capital Markets Buy
2018-07-06 Herabstufung B. Riley FBR, Inc. Buy → Neutral
2018-03-19 Fortgesetzt Chardan Capital Markets Buy
2018-03-19 Herabstufung Wedbush Outperform → Neutral
2018-01-05 Eingeleitet B. Riley FBR, Inc. Buy
2017-04-04 Hochstufung Chardan Capital Markets Neutral → Buy
2017-02-01 Bestätigt Wedbush Outperform
2016-12-13 Herabstufung Chardan Capital Markets Buy → Neutral
2016-11-30 Hochstufung Chardan Capital Markets Neutral → Buy
Alle ansehen

Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Arbutus Biopharma Corporation a good long term investmentUnstoppable investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Arbutus Biopharma Corporation (NASDAQ:ABUS) Position Cut by Teacher Retirement System of Texas - Defense World

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Arbutus Biopharma Corporation stock priceSuperior stock growth - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

Arbutus Biopharma Corporation Stock Analysis and ForecastDynamic profit opportunities - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about Arbutus Biopharma Corporation stockConsistent high-performance stocks - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

What risks could impact Arbutus Biopharma Corporation stock performanceWealth Building Stock Portfolio - beatles.ru

Jul 18, 2025
pulisher
Jul 15, 2025

Why Arbutus Biopharma Corporation stock attracts strong analyst attentionBreakout Confirmation Tool - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Arbutus Biopharma Corporation stock price move sharplyFree Deep Market Trend Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Arbutus Biopharma Corporation stock performs during market volatilityFree Daily Stock Market Updates - Newser

Jul 15, 2025
pulisher
Jun 26, 2025

Warminster Biopharma Firm Ends $285M Licensing Deal with Chinese Company - BUCKSCO.Today

Jun 26, 2025
pulisher
Jun 25, 2025

Arbutus Biopharma (ABUS) Reacquires China Rights to Lead Drug | - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Arbutus Reacquires Greater China Rights to Imdusiran and - GlobeNewswire

Jun 25, 2025
pulisher
Jun 13, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025
pulisher
Jun 08, 2025

Ameriprise Financial Inc. Makes New $62,000 Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Bank of America Corp DE Acquires 171,906 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Purchases 92,068 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jun 05, 2025
pulisher
May 29, 2025

Deutsche Bank AG Buys 75,212 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 29, 2025
pulisher
May 22, 2025

Northern Trust Corp Has $4.35 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 22, 2025
pulisher
May 18, 2025

Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress - MyChesCo

May 18, 2025
pulisher
May 18, 2025

Mercer Global Advisors Inc. ADV Makes New Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 18, 2025
pulisher
May 18, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 15, 2025

Arbutus: Q1 Earnings Snapshot - CT Insider

May 15, 2025
pulisher
May 14, 2025

Arbutus Biopharma Corp Reports Q1 2025 Earnings: Revenue at $1.8 Million, EPS Misses Estimate with $0.13 Loss - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Arbutus Biopharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Arbutus Biopharma (ABUS) Reports Mixed Q1 Results - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Arbutus (ABUS) Reports Lower Q1 Revenue Amid Promising Treatment Progress | ABUS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 13, 2025

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

May 13, 2025
pulisher
May 10, 2025

Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 - MyChesCo

May 10, 2025
pulisher
May 08, 2025

Wells Fargo & Company MN Acquires 21,768 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 08, 2025
pulisher
May 07, 2025

Arbutus Biopharma (ABUS) Showcases Promising Data on Imdusiran and AB-101 | ABUS Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Arbutus Presents Clinical Trial Data from its Two HBV - GlobeNewswire

May 07, 2025
pulisher
May 06, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Barclays PLC - Defense World

May 06, 2025
pulisher
May 05, 2025

Invesco Ltd. Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 05, 2025
pulisher
May 02, 2025

Arbutus Biopharma Corp (ABUS) is a good investment, but the stock may be overvalued - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Arbutus Biopharma Corp (ABUS) With A Potential Upside Of More Than -139.44% - Stocksregister

May 01, 2025
pulisher
May 01, 2025

Arbutus Biopharma Corp (ABUS) looking to reclaim success with recent performance - Sete News

May 01, 2025
pulisher
May 01, 2025

Legal & General Group Plc Has $388,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Arbutus Biopharma Corp [ABUS] Insider Activity: An Update for Investors - knoxdaily.com

Apr 30, 2025
pulisher
Apr 28, 2025

Arbutus Biopharma Corp expected to post a loss of 10 cents a shareEarnings Preview - TradingView

Apr 28, 2025
pulisher
Apr 26, 2025

Stock Market Recap: Arbutus Biopharma Corp (ABUS) Concludes at 3.12, a -1.58 Surge/Decline - DWinneX

Apr 26, 2025
pulisher
Apr 25, 2025

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Apr 25, 2025
pulisher
Apr 24, 2025

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress - MyChesCo

Apr 24, 2025
pulisher
Apr 23, 2025

Arbutus Biopharma Corp (ABUS)’s stock price in review: A technical analysis - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 21, 2025

Alliancebernstein L.P. Has $393,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 21, 2025
pulisher
Apr 19, 2025

Franklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 19, 2025

Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):